drugset / Trial / NCT00983996
Fasting Study of Alendronate Sodium Tablets (10 mg) and Fosamax Tablets (10 mg)
RandomizedCrossoverOpen-label
Summary
The objective of this study is to investigate the bioequivalence of Mylan's alendronate sodium 10 mg tablets to Merck's Fosamax 10 mg tablets following a single, oral 40 mg (4 x 10 mg) dose administration under fasting conditions.
Timeline
- Start
- 2002-06
- Primary completion
- 2002-07
- Completion
- 2002-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Alendronic Acid | Small molecule | 10 mg | Oral |
Indications
No indication recorded.